Becton, Dickinson and Company company logo

# RNN 2nd Gen Model Becton, Dickinson and Company Surgical & medical instruments

Prediction models:
Subscribe >> Deal exit on
Sept. 20, 2019
Deal entry on
Sept. 20, 2019
36.97%Expected margin
50.00% successful of 2 deals
$ 253.59 Last close price
at 30-aug-2019


Model's trade recommendations No return for period yet

-2.02% Annual return

$61.29B Market Cap

β 1.15  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period
52wk return
52wk Range
Sortino ratio -0.61
Sharpe ratio -0.61
Norm. RMSE 35.51%
Downside risk 3.75%
Volatility 0.00%
  • 3.00 (1.30%) Div (Yield)
  • STRONG BUY Analysts consensus recommendation

Becton, Dickinson & Company is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues.

Industry sector: Medical

Sector classification: Surgical & medical instruments

Deep Learning based analysis and prediction model for Becton, Dickinson and Company (BDX) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for BDX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a regular basis.

Float 264M
P/E 23.88
Shares Outstanding 266M
% Held by Insiders 1.00%
% Held by Institutions 83.70%
EPS (last reported FY) $9.48
EPS (last reported Q) $2.48
EPS, estimated (last reported Q) $2.40
Total revenues $12 B
Net income $1 B